Navigation Links
Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
Date:11/5/2007

available to you."

Rogers says that the information that she received from Vela gave her confidence and that she "didn't have to second guess or wonder if I made the right decision" when it came time for her to choose her treatment. But she also says that Vela provided something even more important.

"When you first find out that you have to go on dialysis you're terrified," said an emotional Rogers. "The most important thing she did was to take that fear away. She was there for me, she stayed there for me, and I know that even today I have someone that I can count on."

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

References

1. Rankin, S.H., & Stallings, K.D. (2001). Patient Education: Principles

and Practice. (4th ed). Philadelphia: Lippincott., 78-129.

2. Yeoh, et. al. (2003). Impact of predialysis care on clinical outcomes.

Hemodialysis International, 7(4), 338-341.

3. Klan, B. et. al. (1998) Predialysis patient education: effects on

functioning and well-being in uraemic patients. Journal of Advanced

Nursing, 28(1), 36-44


'/>"/>
SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
8. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
9. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the ... treated in a Phase 1b clinical trial of ... a proprietary small molecule,inhibitor of thioredoxin, a protein ... growth, survival and drug resistance of,many cancers., ...
... to Healthcare Organizations through CSC,s ... ... CSC (NYSE: CSC ) today,announced that its enterprise ... FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes and incorporates ...
... (OTC BB BSTC.OB-News) today announced that it sold ... stock priced at $15,per share for aggregate proceeds ... certain private investors on June 9, 2008. The ... at a premium over the,market price., BioSpecifics ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3CSC Adds Content Management to Hosted Healthcare Offering 2
(Date:9/21/2014)... years, new strains of bacteria have emerged that resist ... including drug-resistant forms of tuberculosis and staphylococcus, infect more ... 23,000. Despite the urgent need for new treatments, scientists ... the past decade. , MIT engineers have now turned ... gene-editing system that can disable any target gene, they ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... imaging technique to track the effects of next-generation nanomedicines ... Strathclyde academic. Professor Dr. M. N. V. Ravi ... of Pharmacy and Biomedical Sciences, believe an advanced form ... boost developments in the field of nanomedicines, the encapsulation ...
... the collaboration between Janssen, J&J Innovation, VIB, KU Leuven ... in translating basic molecular insights to diagnostics and therapeutics ... are committing up to 5 million Euros for this ... research projects from VIB, KU Leuven and UZ Leuven. ...
... obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be ... The 95th Annual Meeting & Expo of The Endocrine Society. ... 15 Adolescent Health (10 a.m. PDT): New insights ... conditions including eating disorders and gender identity disorder. ...
Cached Biology News:Nanomedicines' impact on patients under the microscope 2Nanomedicines' impact on patients under the microscope 3Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases 2
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 2800mL PYREX Fernbach-style culture flasks have triple ... flask bottom to achieve maximal oxygen transfer ... large marking spot., A wide range of ... including:, Polypropylene colored caps for ease ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: